2 results match your criteria: "Lucia M. Novak is a director at Riverside Diabetes Center[Affiliation]"
Bolstering your armamentarium with SGLT2 inhibitors.
Nurse Pract
October 2017
Lucia M. Novak is a director at Riverside Diabetes Center, Riverside Medical Associates, P.A., Riverdale, Md. Davida F. Kruger is an NP at Henry Ford Health System, Detroit, Mich.
Sodium-glucose cotransporter-2 inhibitors have a unique mechanism of action in the kidneys that causes glucosuria, which lowers plasma glucose. They are also associated with reduced body weight and BP, and a low incidence of hypoglycemia. This article reviews the pharmacologic profiles and clinical implications of canagliflozin, dapagliflozin, and empagliflozin.
View Article and Find Full Text PDFBolstering your armamentarium with SGLT2 inhibitors.
Nurse Pract
June 2017
Lucia M. Novak is a director at Riverside Diabetes Center, Riverside Medical Associates, P.A., Riverdale, Md. Davida F. Kruger is an NP at Henry Ford Health System, Detroit, Mich.
Sodium-glucose cotransporter-2 inhibitors have a unique mechanism of action in the kidneys that causes glucosuria, which lowers plasma glucose. They are also associated with reduced body weight, BP, and a low incidence of hypoglycemia. The pharmacologic profiles/clinical implications of canagliflozin, dapagliflozin, and empagliflozin are discussed in this article.
View Article and Find Full Text PDF